



Lumiere Health  
International

# POLICY BRIEF

*NAVIGATING THE BIOSECURE ACT:  
A MULTIDIMENSIONAL ANALYSIS*

Prepared By

Aldo Martinez

April 9th, 2024

# Executive Summary

This policy brief, *Navigating The BioSecure Act: A Multidimensional Analysis*, highlights key aspects and implications of the BioSecure Act (the Act), a significant legislative proposal impacting the U.S. biotechnology sector and its relations with foreign entities, particularly in the context of national security. The Act, introduced to Congress in January 2024, aims to regulate federal contracts with biotech firms linked to foreign adversaries, with a notable focus on China, Russia, Iran, and North Korea. The proposal seeks to safeguard national security by limiting the procurement of biotech products and services from these companies and aims to prevent U.S. taxpayer funds from supporting biotechnological research that could benefit foreign adversaries. The Act also endeavors to restrict the transfer of American genomic data to foreign governments, notably China. This document provides a comprehensive analysis, offering insights into the legislative context, potential implications for corporate strategy, considerations for businesses and international relations, and potential pathways forward for stakeholders within the biotech sector.

The biotechnology sector's rapid growth, with a forecasted surge from \$1,452.30 billion in 2023 to \$4,482.21 billion by 2032, underscores the significance of the BioSecure Act's potential impact. The document provides stock market analysis to support the analysis of potential implications to companies' profitability. The legislative measure has garnered bipartisan support, indicating a broad recognition of its strategic importance to national security and the stability of certain aspects of the biotech industry. The Act's progress through Congress, including discussions and a notable committee vote, suggests active legislative engagement and potential for further deliberation.

Critical areas of concern include the Act's impact on innovation, the definition of "biotechnology companies of concern," and its implications for U.S. biotech competitiveness and international relations. The document proposes alternative policy recommendations, such as enhancing international partnership programs, adopting a voluntary compliance framework, and supporting research and development through incentives. These suggestions aim to balance national security interests with the need to foster innovation and international cooperation in the biotech sector.

To illustrate and bring to life the broader geopolitical and economic implications of such legislative measures, this document includes a case study of ZTE Corporation, a Chinese multinational telecommunications company, that experienced operational challenges following U.S. regulatory actions. This case study explores the implications of the U.S. ban on ZTE, the company's response, and the broader geopolitical context, and serves as a pertinent example for business leaders to envisage potential implications should The US Congress enact the BioSecure Act.

The document concludes by emphasizing the importance of strategic agility and adaptability for biotech companies in navigating the evolving regulatory landscape introduced by the BioSecure Act. This executive summary/abstract encapsulates the document's comprehensive analysis, offering insights into the legislative context, strategic considerations, and potential pathways forward for stakeholders within the biotech sector.


Respectfully,

Aldo M. Martinez, MBA, MPA  
Lumiere Health International, Inc.

## Overview of the BioSecure Act

The *BioSecure Act* (HR. 7085) (S. 3558) is a pivotal element of the U.S. national security framework, with implications that may ripple through the biotechnology industry. It could impact the stock market valuations of biotech firms, affecting investor sentiment and market behavior. The Act also carries weighty diplomatic consequences, particularly for U.S.-China relations, potentially shaping joint initiatives, trade, and tech transfer. A thorough examination of the Act's specific concerns is essential to grasp its full scope. Pinpointing these concerns will enable the crafting of balanced, refined strategic options tailored to the complex and evolving landscape of the industry. This policy brief is organized in the following order: First, the brief presents an overview of the biotechnology industry's current state and future outlook. Second, it delves into a political analysis surrounding the BioSecure Act. Third, the strategic implications of the Act are evaluated, highlighting its significance. Next, it critically examines certain specific areas of concern within the Act. Following this, the brief offers various policy alternatives for consideration. Subsequently, a case study is presented to illustrate the practical impacts of government policies on businesses. Finally, the brief outlines adaptive strategies for businesses to adjust to regulatory changes. These elements provide a roadmap through the complexities of the BioSecure Act and its implications for the biotech sector.

*Biotechnology Market Size, By Region (USD Billions)*



### **Biotechnology Market**

The biotechnology sector is expansive and rapidly growing, providing a crucial backdrop for understanding the potential impact of the BioSecure Act on this industry. Grasping the sector's size and trajectory helps contextualize the Act's implications, offering insight into regulatory, economic, and innovation-related consequences within biotech. The biotechnology sector is experiencing a robust growth phase, with its market value expected to increase sharply from \$1,452.30 billion in 2023 to \$1,639.64 billion in 2024.<sup>ii</sup> Looking further ahead, forecasts indicate a surge to \$4,482.21 billion by 2032, demonstrating a compounded annual growth rate (CAGR) of 13.4%.<sup>iii</sup> This surge is driven by breakthroughs in DNA sequencing, advances in nanobiotechnology, and significant growth in health-related applications.<sup>iv</sup> The United States, recognized as the bedrock of the North American biotech industry, continues to lead through aggressive research and development, heavy healthcare expenditure, and the integration of personalized medicine approaches.<sup>v</sup> American biotech giants and international firms with substantial U.S. operations are the vanguards of this expansion.<sup>vi</sup> Their focus on providing cutting-edge technology, products, and services, combined with strategic mergers and dedicated research efforts, is instrumental in propelling the industry's rapid ascent.<sup>vii</sup>

### **Political Analysis Framework of The BioSecure Act**

#### **Background and Progress of the BioSecure Act**

Introduced to the U.S. Congress on January 25<sup>th</sup>, 2024, the BioSecure Act (the Act) is designed to regulate federal contracts with biotech firms linked to foreign adversaries, specifically targeting companies from China, Russia, Iran, and North Korea.<sup>viii</sup> This legislation seeks to safeguard national security by restricting the acquisition of biotech products and services from these high-risk companies.<sup>ix</sup> Moreover, it intends to prevent U.S. taxpayer dollars from inadvertently funding biotechnological research and development that could benefit foreign powers.<sup>x</sup> A key goal of the Act's sponsors is to halt the flow of American genomic<sup>xi</sup> information to the Chinese government.<sup>xii</sup>

#### **Policy Window, Bipartisan Dynamics, & Stakeholder Engagement**

The BioSecure Act, backed by bipartisan support, underscores a timely, united response to fortify national security and the biotech industry's stability. The collaboration of experts and legislators, led by Senator Gary Peters and co-sponsors from both parties, signals a strategic alliance as they move to present a refined bill and a positive committee endorsement to the Senate, marking a significant step towards reinforcing biosecurity.

"Co-leads in the House include Select Committee members Reps. Neal Dunn (R-FL), Seth Moulton (D-MA), and Jake Auchincloss (D-MA), while Sens. Bill Hagerty (R-TN) and Gary Peters (D-MI) Chairman of the Homeland Security and Governmental Affairs Committee, Mitt Romney (R-UT), and Roger Marshall (R-KS) have already introduced corresponding legislation in the Senate."<sup>^^</sup>

The House of Representatives version (*HR. 7085*) was introduced in the House on January 25th and referred to the House Committee on Oversight and Accountability<sup>xiii</sup>. On March 6, 2024, the Senate Committee on Homeland Security and Governmental Affairs discussed and deliberated (*S. 3558*) (the Senate's version). The committee voted 11:1 to advance *S. 3558* to the Senate floor after an 11:1 committee vote.<sup>xiv,xv</sup> This suggests movement in the Senate for further deliberation.

In the sessions, Senator Rand Paul, who cast the sole "nay" vote on the panel, voiced apprehensions regarding concealed motives of anti-competitiveness within the legislation.<sup>xvi</sup> "By banning certain companies, we're advantaging certain other companies,"<sup>xvii</sup> he stated, suggesting that, "People are taking advantage of anger towards China to do parochial, protectionist things for their particular state."<sup>xviii</sup> Additionally, he expressed concern over the potential impacts of the Act's disruption to supply chains, which he believes have not been thoroughly evaluated.<sup>xix</sup> The remaining committee members, comprising eight Democrats and three Republicans, unanimously supported the bill with "yeas."<sup>xx</sup> Meanwhile, during the House committee meetings, Mr. Krishnamoorthi (D-IL) stated, "it is unacceptable for U.S. taxpayer dollars to be used to subsidize biotech companies of our foreign adversaries."

Given the early stage of the BioSecure Act, fluctuations in the legislative process are expected. The Act's final form will be crafted through political negotiation, careful analysis of pertinent data, and input from experts in the field.

### Stakeholder Interests & Advocacy

The expected advocacy activities by entities within the biotechnology and pharmaceutical sectors, alongside privacy and civil liberties groups, underscore the influential participation these stakeholders are likely to exert on the Act's formulation. Central to these deliberations are bipartisan legislators and advocacy coalitions positioned to advocate for the BioSecure Act vigorously. Such endeavors will necessitate a strategic amalgamation of concerted negotiations, lobbying, educational outreach, and the rallying of industry backing to underscore the importance of the Act.

From a political perspective, Republicans, Democrats, and Independents may negotiate on a wide range of issues and interests central to their political strategies. Republicans may underscore the BioSecure Act's contribution to national security and the safeguarding of the U.S. biotech economy, reflecting the policy dimension's emphasis on protecting America's biotechnological assets. Democrats, on the other hand, would likely focus on the protection of personal health information and genetic data, their approach resonates with the political dimension's concerns over privacy and data security. Meanwhile, Independents and Moderates may perceive the Act as a pragmatic response to a significant threat, which corresponds with the strategic coupling of problem, policy, and political dimensions. The bipartisan bill's targeted strategy aims to maximize appeal across diverse political spectrums.

## Strategic Implications of the BioSecure Act

### Economic Implications and Market Impact

Following the introduction of the BioSecure Act in January 2024, the stock market's response was swift. Certain companies experienced significant declines in market value.<sup>xxi</sup> In fact, WuXi AppTec and Wuxi Biologics reportedly lost \$20 billion from their market capitalizations.<sup>xxii</sup> WuXi Biologics' stock price<sup>1</sup> has decreased 55% from January 2024 to April 2024.<sup>xxiii</sup> See Figure 2.




Figure 2: Stock Price Reaction<sup>2</sup> to The Introduction of BioSecure Act, January 2024.

If passed, the Act will affect strategic realignments within the biopharmaceutical industry. Companies will need to recalibrate their supply chains and reconsider partnerships

<sup>1</sup> In December 2024 WuXi stock plummeted 24%<sup>1</sup> after missing revenue forecasts by \$400M<sup>1</sup>

<sup>2</sup> Closing price at the end of December 2023 as the starting point through April 2024 were used to calculate the percentage decrease.

<sup>^^</sup> US House of Representative: The Select [Bipartisan] Committee on the Chinese Communist Party

with other companies to dampen the regulatory shocks to their corporate strategies. Notably, companies such as “WuXi, AppTec, BGI, and any subsidiary, parent affiliate, or successors of such entities”<sup>xxiv</sup> (all mentioned in the Bill) will imminently face stringent mandates and restrictions, which could further impact business operations and their stock prices as witnessed with WuXi Biologics. See Appendix for company profiles. In response, companies issued immediate statements declaring independence from foreign military or governmental influence<sup>xxv</sup>. They also articulated substantiated concerns about potential impacts on supply chains, potentially escalating healthcare costs.

To understand potential business implications, we can assess the impact of regulatory restrictions such as the Department of Commerce’s (DOC) Denial Order and the National Defense Authorization Act (NDAA)<sup>3</sup>. In April 2018, the DOC imposed a Denial Order on ZTE Corporation, and shortly after The NDAA Fiscal Year 2019 imposed restrictions<sup>xxvi</sup> on multinational telecommunication companies. Companies affected were ZTE, Huawei<sup>xxvii</sup>, and others<sup>xxviii</sup>, with restrictions to their business operations in the US due to national security concerns. The case study, ZTE's Operational Halt Due to US Ban on page 6, outlines ZTE's trajectory and the consequences it faced post-NDAA enactment. While ZTE is a telecommunications company, its experience may serve as a predictive model for the outcomes companies might expect if barred from operating within the US market.

Companies should proactively assess readiness and develop alternative strategies to counter potential disruptions or economic losses as seen with WuXi Biologics and ZTE Corporation.

### ***National Security and Public Health Concerns***

The BioSecure Act targets national security and public health threats posed by foreign biotechnology firms, particularly those affiliated with adversarial nations. This legislation emerges amid escalating geopolitical tensions and a critical examination of the U.S. biotechnological sector's security posture. Recent incidents, including security breaches where sensitive American biotechnological information was compromised, underscore the necessity of this Act.

The Act's implications extend into the biopharmaceutical industry, potentially hampering research and development (R&D) progress. The Act could impose constraints on innovation and technological development. Complete Genomics stated in an open letter to stakeholders that the BioSecure Act will impact innovation by “slowing our

sector's progress, stifling our innovation, and making it harder for researchers to make those important breakthroughs in areas like Alzheimer's and oncology.<sup>xxix</sup>” Such constraints on R&D could lead to increased healthcare costs and restricted access to innovative, life-saving medications. This situation reflects the complex balance between ensuring national security and sustaining the dynamic growth and accessibility of the biopharmaceutical sector.

### ***Implications on International Relations***

The Act aligns with past laws—such as the NDAA—aimed at limiting business contracts with entities that pose national security risks. The NDAA enactment prompted a swift response from China, and it will likely respond to the Act with stringent measures.

From a wider perspective, if the BioSecure Act passes, it could strain U.S.-China relations and global trade dynamics, similar to the tensions experienced following the enactment of the National Defense Authorization Act (NDAA), which targeted Chinese telecommunications companies like ZTE. The potential for retaliatory measures from China remains an area of concern. Chinese companies and officials may view such legislation as protectionist and may issue statements or take action in response. While direct-specific retaliatory measures in response to the NDAA were not detailed in the sources reviewed, on September 19, 2020, in response to perceived threats to its national interests, China enacted the Unreliable Entities List (UEL),<sup>xxx,xxxi</sup> targeting foreign companies and individuals whose actions are deemed harmful to China's sovereignty, security, or development, or discriminatory against Chinese entities. This list is part of a broader strategy, including the Anti-Foreign Sanctions Law (AFSL),<sup>xxxii,xxxiii</sup> aimed at countering foreign sanctions and actions viewed unfavorably by China.

The Unreliable Entities List (UEL), as applied by China in February 2023 to designate Lockheed Martin Corporation and Raytheon Missiles & Defense, showcases Beijing's strategic use of legal and regulatory frameworks to counter foreign policies perceived as adversarial.<sup>xxxiv</sup> This action, entailing import-export bans and investment restrictions alongside significant financial penalties tied to arms sales to Taiwan, evidences China's proactive stance in safeguarding its national security interests, particularly concerning Taiwan. The move indicates China's willingness to employ rigorous measures in retaliation to foreign actions that threaten its sovereignty.

In parallel, the United States has taken further steps to safeguard its national security by potentially banning federal

---

<sup>3</sup>The NDAA for Fiscal Year 2019 impacted ZTE Corporation through Part A, Section 889.

agencies from engaging with foreign companies, most notably Chinese companies, identified as security risks or companies involved in transactions with countries like Iran or Russia. This measure reflects the escalating tension between the two powers, underscoring the strategic maneuvers aimed at mitigating perceived threats.

The emergence of the BioSecure Act in the U.S., targeting foreign biotechnology firms classified as security concerns, further illustrates the intensification of these tensions. This legislative proposal, by potentially prohibiting federal dealings with entities labeled as "companies of concern," mirrors earlier actions against telecommunications companies and indicates a comprehensive approach to national security across different industrial sectors.

Given this pattern of legislative and regulatory responses between these two superpowers, it is logical to anticipate that China might adopt countermeasures in response to the BioSecure Act. This expectation is grounded in a history of reciprocal actions, where China has consistently demonstrated its capacity and inclination to retaliate against U.S. policies through similar sanctions and restrictions, leveraging its Unreliable Entities List and other tools to assert its geopolitical and security interests.

Thus, the evolving dynamics between the U.S. and China, manifested through legislative actions and retaliatory measures, underline the complexities of international trade and diplomacy. It underscores the necessity for multinational corporations to navigate carefully within this intricate geopolitical landscape, assessing potential risks and formulating strategies that accommodate the regulatory environments of both nations.

### ***Important Considerations***

While the fate of the BioSecure Act remains uncertain, cautious optimism exists due to its bipartisan backing and strategic importance. Stakeholders in the life sciences and biopharmaceutical industries are advised to prepare for regulatory changes proactively ensuring operational consistency and compliance. The Act's progress requires monitoring as it could reshape industry practices, impact market trends, and influence international trade relations.

---

## **Critical Examination: Addressing the BioSecure Act's Areas of Concern—A Balancing Act**

Like any landmark piece of legislation in its initial stage, areas of concern arise that warrant careful examination. Addressing these concerns is vital to mitigate risks and prevent potential unintended consequences. To that end, it is essential to recognize that the Act must balance securing

national interests and maintaining the U.S.'s position as a leader in global biotechnological innovation. Achieving this balance is crucial in protecting public health and national security while encouraging innovation and business growth.

### ***Stifles Innovation***

The legitimate concern regarding the stifling of innovation demands a strategic and nuanced approach. The BioSecure Act aims not to inhibit collaboration but to ensure that such partnerships do not jeopardize national security. It establishes a framework that permits collaborations, contingent upon a thorough "evaluation"<sup>xxxv</sup> process designed to protect intellectual property and sensitive biotechnological data without completely disrupting scientific exchanges. Additionally, by fostering innovation both domestically and among allied nations, the Act has the potential to spur a new wave of research within secure and trusted networks, leading to breakthroughs that may not have been possible in a less regulated setting.

Nevertheless, the "evaluation of certain biotechnology entity"<sup>xxxvi</sup> process itself emerges as a critical area requiring clarity and transparency. The Act must delineate the boundaries of the vetting process. This clarity will help ensure the verification process enhances security without unduly hindering the progress of scientific research and collaboration or imposing unreasonable administrative and compliance burdens on companies.

### ***Defining 'biotechnology companies of concern'***

The Act's broad definition of "biotechnology companies of concern,"<sup>xxxvii</sup> while intended to protect national security, may introduce significant governmental operational challenges. The Act mandates a collaborative approach among federal agencies, integrating diverse intelligence and geopolitical insights. This process, though essential for a comprehensive assessment, may slow down the designation of companies as concerns. And while the companies BGI, MGI, Complete Genomics, Wuxi, and Apptec,<sup>xxxviii</sup> are explicitly named in the bill, it may encompass a wide range of entities, necessitating precise criteria to prevent over-generalization that could inhibit innovation and collaboration in the biotech sector and may invite legal challenges.

The Act includes provisions for waivers and exceptions to offer flexibility, yet it may require explicit criteria to avoid creating loopholes that could undermine the Act's objectives. The need to align compliance with international cooperation further complicates its implementation. Furthermore, adhering to the Act's requirements will likely raise administrative costs and complexity for companies, potentially impacting their operations and stifling innovation. Thus, the Act demands a careful implementation strategy that minimizes administrative burdens, clearly outlines criteria for waivers, and supports global scientific collaboration without compromising security interests.

### ***Impact on US Biotech Competitiveness***

The Act's targeting of foreign biotechnology firms for national security purposes necessitates an evaluation of its broader impact on the U.S. biotech industry's competitiveness. Such measures risk provoking retaliatory actions—as previously discussed—that could curtail U.S. companies' access to vital international markets and disrupt global supply chains, potentially elevating operational costs and delaying product development. This indirect influence could diminish the competitiveness of domestic biotech firms.

The vitality of the global biotech ecosystem is underpinned by international cooperation and idea exchange. Imposing restrictions on foreign entities may weaken these collaborative ventures in several key areas: 1) international technical transfer,\* 2) talent acquisition, 3) foreign direct investments in the US, 4) collaborative research, 5) supply chains. For biotechnology companies, these key areas are crucial sources of competitive advantage. Furthermore, the intricate regulatory landscape emerging from these measures might redirect resources of U.S. biotech firms from their primary research and development objectives, thereby impacting their international standing.

To preserve the U.S. biotechnology sector's competitiveness while mitigating security risks it would be critical to adopt a measured approach that harmonizes security considerations with innovation, global collaboration, market access, and regulatory adaptability is crucial. Such a strategy would ensure continued innovation and growth of the U.S. biotech industry within a secure, yet globally integrated and cooperative ecosystem.

## **Alternative Innovative Policy Recommendations**

### ***Enhanced International Partnership Programs***

Modeled after the National Institutes of Health (NIH) public-private partnerships program, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV),<sup>xxxix</sup> language within the act mandating the creation of the “Enhanced International Partnership Programs” could significantly reinforce the U.S. biotech and pharmaceutical sectors by setting up secure, thoroughly evaluated channels for global collaboration. These initiatives target could ensure that biotechnology and pharmaceutical research adhere to the most stringent standards for data protection and intellectual property security. Emphasizing these protected channels would allow the U.S. to more effectively participate in the global innovation ecosystem without endangering national security.

These programs could be designed to enable the smooth and secure sharing of research outcomes, data, and technology while nurturing a conducive environment for joint ventures and collaborations.

Furthermore, the Enhanced International Partnership Programs could act as a benchmark for other sectors, illustrating the possibility of harmonizing security imperatives with the advantages of international cooperation. By clearly outlining safe collaboration routes, these programs could mitigate the uncertainties and risks typically associated with international biotech and pharmaceutical endeavors, thereby drawing a broader array of global partners willing to collaborate within a secure and respectful framework.

In essence, by fortifying these secure collaborative networks, the U.S. not only protects its biotechnological interests but also asserts itself as a pivotal leader in the ethical and responsible progression of global biotechnology and pharmaceutical research. This leadership could significantly influence the setting of new international standards for collaboration that equally prioritize innovation and security.

### ***Voluntary Compliance Framework***

Adopting a voluntary framework that encourages companies to comply with strict security and intellectual property (IP) protection standards could present an effective regulatory strategy. For example, the FDA's Pharmaceutical Quality Standards Working Group (PQSWG) is aimed at enabling and monitoring voluntary quality standards.<sup>xl</sup> Additionally, other organizations already promote voluntary frameworks such as the International Organization for Standardization (ISO) or the International Council for Harmonization (ICH). This approach would allow firms to achieve a certification denoting adherence to elevated security standards. Certified companies could benefit from streamlined regulatory reviews, etc. A voluntary compliance framework may incentivize companies to elevate their security and IP protection practices and promote industry-wide self-regulation. Incorporating such incentives is likely to boost compliance levels, spur innovation, and enhance market access.

This regulatory model suggests that incentivizing compliance through tangible rewards can be as impactful as implementing stringent regulatory mandates. Rewarding firms that achieve or surpass established security and IP standards could help the industry meet regulatory goals while sustaining its innovative capacity and competitive advantage.

\* Tech transfer may be an area of security concern where more stringent regulatory compliance measure may be used. See next section "alternative innovative policy recommendations" on how to potentially address this concern.

***Incentive-Based Research and Development Support***

The Incentive-based R&D Support program aims to boost U.S. biotech and pharma sectors by offering financial incentives like tax breaks, grants, or subsidies, encouraging domestic R&D, and securing global partnerships. This financial support can foster public health and technological advancement in areas vital to national interests. Tax reliefs ease immediate costs, promoting long-term innovation, while grants and subsidies support emerging companies and priority research. Additionally, faster approval for local R&D could speed up market access. Together with international cooperation, these measures aim to strengthen domestic research, enhance industry resilience, and ensure controlled innovation.

**Case Study: ZTE's Operational Halt Due to US Restrictions**


This case study<sup>‡</sup> explores the implications of the U.S. ban on ZTE, the company's response, and the broader geopolitical context, and serves as a pertinent example for business leaders to envisage potential implications should the BioSecure Act pass.

In April 2018, ZTE Corporation, China's second-largest telecom equipment manufacturer, faced a critical challenge that led to the halting of its main business operations. The United States Department of Commerce (DOC) initiated regulatory restrictions on ZTE via a Denial Order<sup>xi</sup>. Shortly after, the US government enacted the National Defense Authorization Act (NDAA) in Fiscal Year 2019<sup>xiii</sup> directly impacting ZTE.<sup>xliii</sup> The NDAA prohibited U.S. agencies and government contractors from supplying or buying components and technology from ZTE<sup>xliv</sup>. These actions came after ZTE was found to have violated U.S. export restrictions by illegally shipping goods to Iran and North Korea. The DOC penalized ZTE with a \$1.4B fine and a Denial Order.<sup>xlv</sup>

***Operational Halt and Supply Dependency***

Following the U.S. government's retroactive Denial Order.<sup>xlvi</sup> ZTE Corporation halted its principal operations while continuing to incur fixed costs, unable to buy or sell products and services to US agencies or government contractors. The company's reliance on U.S.-sourced components, especially from technological giants like Qualcomm and Intel, which constitute nearly one-third of its inventory, has become starkly apparent. ZTE's halting operations, among other factors beyond the scope of this paper, highlighted its vulnerability and the critical impact of American suppliers on its business continuity, as reflected in a 26% decline in net margin.<sup>4</sup>

*Figure 3: Income Statement Data (Historical and Forecast)*



<sup>4</sup> COVID-19 disruptions may have impacted sales and operations, but ZTE management confirmed, via news sources, operations stopped immediately after the Denial Order was issued. The immediate enactment of NDAA restrictions compounded business challenges.

<sup>‡</sup> Based on news reports from Reuters and The Hill.



ZTE's financial health, however, shone through as it strategically upheld its fiscal stability with cash reserves. Additionally, ZTE negotiated agreements with the US government to diligently meet its legal and commercial commitments in alignment with prevailing regulations. Notwithstanding, sweeping regulatory restrictions like the Denial Order and policies like the NDAA have long-run effects, prompting companies to innovate and change strategic direction, which could be costly and risky. Industry analysts speculated that ZTE's path to finding suitable non-U.S. suppliers would be arduous, and the ban could seriously impede the corporation's ability to compete globally. ZTE's profitability began to change course in 2021, two years after the abrupt operational stoppage. See Figure 3.

The Denial Order and NDAA's threat to ZTE's market position was profound. It threatened ZTE's role in the competitive global telecom landscape. The complexities of trade skirmishes between the United States and China provided a tense geopolitical canvas, influencing China to enact the Unfavorable Entities List (UEL) as part of the Anti-Foreign Sanctions Law (AFSL) on September 2020,<sup>xlvii,xlviii</sup> aimed at countering foreign sanctions and actions viewed unfavorably by China.

The market dynamic and policy measures that unfolded necessitated a comprehensive reevaluation of ZTE's corporate and operational strategy, compelling the company to seek alternative pathways to maintain its competitiveness in an era marked by stringent regulatory challenges and geopolitical confrontations.

## **Analysis of ZTE's Financial & Business Performance Post-Regulatory Restrictions**

### ***Financial Analysis***

The aftermath of the implementation of the Denial Order and NDAA placed ZTE under a magnifying glass, with analysts scrutinizing the telecom giant's ability to navigate through a transformed regulatory and competitive landscape. Nevertheless, ZTE recalibrated its financial outlook and intelligently adapted its corporate strategy to this new reality.

A deeper dive into ZTE's financials and strategic responses reveals the Denial Order and NDAA's impact on ZTE's business. While total sales increased by 7% (potentially supported by sales of other business units)

from 2019 to 2020, net margins in the same period tell a different, nuanced story. Net margin,<sup>5,xlix</sup> a key financial metric, measures how well a company generates profits from its sales and whether operating costs are used efficiently. Eleven percent of sales come from enterprises and government organizations and a portion of 13.6% of sales come from the US.<sup>6</sup> This suggests that after halting operations, inventory costs (part of operating costs) and sourcing inventory from elsewhere imposed additional costs for the company. See Figure 2. Hence, manifesting in lower profitability for ZTE.

ZTE's financial statements indicate a renewed focus on diversification and innovation as key drivers. The company's emphasis on R&D investment, which accounted for 13.83% of its operating revenue in 2019 (an 8.5% increase from 12.75% prior year)<sup>l</sup> suggests a strategic pivot toward strengthening its technology and product competitiveness. This may also suggest a focus on lowering costs of production, optimizing supply chains, or seeking new markets through R&D initiatives in response to restrictions in the US.

### ***Adaptive Business Strategies***

Investing heavily in R&D was key to ZTE's strategy for sustainable growth. To address these multifaceted challenges, ZTE placed strategic emphasis on prioritizing its key business areas and pushing forward with technological advancements. They also stressed adherence to compliance, and the importance of maintaining high operational standards, and diligently worked to expand business activities. This strategic approach has been instrumental in retaining and enhancing its presence in the global market.<sup>li</sup> The company broadened its supply chain and ventured into new markets to diminish dependence on unpredictable geopolitical conditions and lessen the impact of regulatory changes, enhancing its resilience against disruptions.<sup>lii,liii</sup> The investment innovative strategies aimed to create value and secure competitive advantages, while mitigating potential losses from market volatility and regulatory pressures.

Strengthening compliance mechanisms was also a critical focus to forestall future regulatory sanctions. ZTE is "required to retain a team of special compliance coordinators selected by and answerable to the Department's Bureau of Industry and Security (BIS) for 10 years."<sup>liv</sup> By emphasizing adherence to regulations, ZTE sought to minimize further legal exposure and strengthen investor trust in its governance.

---

<sup>5</sup> Net margins and other key financial metrics were calculated using historical financial data from ZTE's financial statements and market data.

<sup>6</sup> Assumes a potentially greater proportion of sales came from government agencies and from the US market before the Denial Order and NDAA enactment in 2019.

The ZTE narrative exemplifies the susceptibility of global enterprises to geopolitical and regulatory dynamics, illustrating the vital role of strategic adaptability in addressing corporate challenges within complex industry dynamics.

---

## **Conclusion: Future-Proofing Biotech: Strategic Agility in the BioSecure Era**

In light of the impending BioSecure Act, it's prudent for leaders within the biotechnology sector to approach the future with both caution and adaptability. This legislative development, while aiming to enhance security and compliance within the industry, introduces a layer of uncertainty akin to the challenges faced by companies navigating the DOC's and NDAA's complexities. The Act is anticipated to significantly influence the operational and compliance landscape, subtly altering market dynamics and potentially impacting financial and growth trajectories.

The emphasis on strategic agility and proactive planning becomes paramount. Biotechnology firms are encouraged to refine their strategic outlook, ensuring that flexibility and innovation are at the core of their operations. This foresight will not only facilitate compliance with new regulatory requirements but also empower firms to swiftly adapt to market shifts, thereby safeguarding their competitive edge and growth prospects.

The coming period demands a nuanced understanding of the potential impacts of the BioSecure Act, advocating for a balanced approach that prioritizes regulatory readiness and strategic innovation. Embracing agility in these ambiguous times will be crucial for biotechnology companies aiming to navigate the evolving landscape successfully, ensuring they remain resilient and thrive in the face of new challenges.

### **About the Author:**

Mr. Aldo Martinez, with a 14-year career in management consulting and healthcare policy, including experience with Big 4 firms, holds an MBA and MPA from Harvard University and completed a biopharma R&D residency at MIT. As the Co-Founder, CEO, and Chairman of Lumiere Health International, he leads the company's strategic vision in healthcare innovation. His role as a Health Policy Advisor has significantly influenced healthcare policy during the COVID crisis, leveraging his expertise in strategic management and legislative analysis. His corporate strategy experience includes advising Fortune 100 companies at PwC and managing Bayer Pharmaceutical's product supply and R&D top 20 global strategic initiatives for enhanced operational efficiency. Also the President-elect of the Harvard Latino Alumni Alliance, he represents over 18,000 Latino alumni worldwide. Mr. Martinez resides in New York City with his family. He is an avid runner and finds joy in cooking for his loved ones, a pastime that complements his professional life by fostering a sense of community and well-being. His career profile combines professional rigor with personal balance, reflecting values of both industry excellence and life's simple pleasures.

## APPENDIX

### **WuXi Biologics (Cayman) Inc.**

WuXi Biologics, operating under WuXi Biologics (Cayman) Inc., is a powerhouse in the biopharmaceutical sector, offering a comprehensive suite of services across the entire drug development process. As of April 2024, WuXi Biologics has a market capitalization of \$7.54 billion, making it the 2017th most valuable company globally.<sup>lv</sup> With a significant global presence, the company leverages cutting-edge technology platforms like WuXiBody for bispecific antibodies, CRISPR for genomic editing, and various microbial expression platforms for producing new proteins and plasmids. WuXi Biologics boasts an expansive footprint with state-of-the-art manufacturing facilities across China, Singapore, Ireland, Germany, and the USA, aiming to support the swift development and manufacturing of biologics at a global scale. Their commitment to innovation is evident in their extensive service offerings, from discovery and development to manufacturing of biologics.<sup>lvi</sup>

### **AppTec**

AppTec, part of the larger WuXi PharmaTech ecosystem, provides comprehensive research, development, and manufacturing services. WuXi AppTec has a market cap of \$18.41 billion, ranking it as the 1012th most valuable company worldwide.<sup>lvii</sup> This segment of WuXi focuses on enabling companies in the pharmaceutical, biotechnology, and medical device sectors to advance their innovations with greater efficiency. Although specific details about AppTec are less widely publicized in the immediate sources, the synergy within the WuXi family underscores a commitment to leveraging scientific expertise and advanced technology platforms to support client needs across the healthcare and life sciences industries.<sup>lviii</sup>

### **BGI Group**

Established in 1999, BGI Group is renowned for its pioneering work in genomics. As of April 2024, BGI Group has a market cap of \$2.37 billion.<sup>lix, lx</sup> It is a cornerstone in the global scientific community, contributing to major genetic research breakthroughs and initiatives. BGI's extensive research and development efforts are geared toward understanding genetic information and harnessing it for medical, agricultural, and biodiversity conservation purposes. The company has been instrumental in numerous international genome projects, offering insights that drive the advancement of genetic research and applications. BGI's commitment to leveraging genomics to improve human health and the global environment marks it as a leader in the biotech field.<sup>lxi</sup>

### **Complete Genomics**

Complete Genomics, acquired by BGI in 2013, specializes in advanced DNA sequencing technologies. Known for its high-quality, cost-effective complete human genome sequencing, Complete Genomics supports a broad spectrum of genomic research by providing detailed and accurate genetic information. As of April 2024, Complete Genomics generated \$1.4 million in revenues, according to NASDAQ.<sup>lxii</sup> This technology enables a deeper understanding of genetic structures and functions, facilitating groundbreaking discoveries in medicine and biology. Complete Genomics emphasizes innovation in sequencing technology to enhance research capabilities and accelerate the pace of scientific discovery.<sup>lxiii, lxiv</sup>

## End Notes (See bibliography for full citation)

- <sup>i</sup> <https://www.polarismarketresearch.com/industry-analysis/biotechnology-market>, at 4.1
- <sup>ii</sup> <https://www.marketdataforecast.com/market-reports/global-biotechnology-market>
- <sup>iii</sup> <https://www.polarismarketresearch.com/industry-analysis/biotechnology-market>
- <sup>iv</sup> Ibis. at 4.2
- <sup>v</sup> <https://www.marketdataforecast.com/market-reports/global-biotechnology-market>
- <sup>vi</sup> <https://www.polarismarketresearch.com/industry-analysis/biotechnology-market>, at 4.5
- <sup>vii</sup> Ibis. at 4.5
- <sup>viii</sup> <https://www.congress.gov/bill/118th-congress/senate-bill/3558?q=%7B%22search%22%3A%22s+3558%22%7D&cs=3&r=1>
- <sup>ix</sup> Ibis.
- <sup>x</sup> <https://www.law360.com/articles/1790797/bills-aim-to-halt-cash-to-chinese-cos-over-genetic-data>.
- <sup>xi</sup> <https://www.whitehouse.gov/briefing-room/presidential-actions/2024/02/28/executive-order-on-preventing-access-to-americans-bulk-sensitive-personal-data-and-united-states-government-related-data-by-countries-of-concern/>.
- <sup>xii</sup> <https://www.ropesgray.com/en/insights/alerts/2024/03/the-biosecure-act-a-review-of-the-bill-responses-and-possible-repercussions>
- <sup>xiii</sup> <https://www.congress.gov/bill/118th-congress/senate-bill/3558?q=%7B%22search%22%3A%22s+3558%22%7D&cs=3&r=1>
- <sup>xiv</sup> <https://www.congress.gov/bill/118th-congress/senate-bill/3558/all-actions?s=3&r=1&q=%7B%22search%22%3A%22S.+3558%22%7D>
- <sup>xv</sup> <https://www.hsgac.senate.gov/wp-content/uploads/Committee-Record-2024-03-06.pdf>
- <sup>xvi</sup> <https://www.ropesgray.com/en/insights/alerts/2024/03/senate-committee-votes-to-send-the-biosecure-act-to-the-senate-floor>
- <sup>xvii</sup> Ibis., as quoted
- <sup>xviii</sup> Ibis., as quoted
- <sup>xix</sup> Ibis.
- <sup>xx</sup> Ibis.
- <sup>xxi</sup> <https://pharmaboardroom.com/articles/new-us-biosecure-act-to-target-chinese-biotechs-wuxi-and-bgi/>
- <sup>xxii</sup> <https://www.wsj.com/business/wuxi-companies-shares-slide-amid-concerns-over-proposed-u-s-bill-bb2827c5>
- <sup>xxiii</sup> <https://finance.yahoo.com/quote/2269.HK/history/>
- <sup>xxiv</sup> <https://www.congress.gov/118/bills/s3558/BILLS-118s3558is.pdf>, at page 7
- <sup>xxv</sup> <https://doc.irasia.com/listco/hk/wuxibiologics/announcement/a240129.pdf>
- <sup>xxvi</sup> <https://www.congress.gov/115/bills/hr5515/BILLS-115hr5515enr.pdf>
- <sup>xxvii</sup> Ibis, at page H. R. 5515—283
- <sup>xxviii</sup> [https://www.acquisition.gov/sites/default/files/page\\_file\\_uploads/889-Flyer-Approved.pdf](https://www.acquisition.gov/sites/default/files/page_file_uploads/889-Flyer-Approved.pdf)
- <sup>xxix</sup> <https://www.completegenomics.com/open-letter-to-genomics-community/>
- <sup>xxx</sup> <https://perma.cc/B7JS-E4PY>
- <sup>xxxi</sup> <https://www.loc.gov/item/global-legal-monitor/2020-10-08/china-government-releases-provisions-on-unreliable-entity-list-regime/>
- <sup>xxxii</sup> Ibis.
- <sup>xxxiii</sup> Ibis.
- <sup>xxxiv</sup> <https://www.reedsmith.com/en/perspectives/2023/03/china-sanctions-us-companies-for-first-time-under-unreliable-entity-list>
- <sup>xxxv</sup> <https://www.congress.gov/118/bills/s3558/BILLS-118s3558is.pdf> at page 6
- <sup>xxxvi</sup> Ibis.
- <sup>xxxvii</sup> <https://www.congress.gov/118/bills/s3558/BILLS-118s3558is.pdf>, at page 7
- <sup>xxxviii</sup> Ibis.
- <sup>xxxix</sup> <https://www.nih.gov/news-events/news-releases/nih-launch-public-private-partnership-speed-covid-19-vaccine-treatment-options>
- <sup>xl</sup> <https://qscompliance.com/establish-voluntary-pharma-quality-standards/>

- 
- <sup>xli</sup> [https://www.zte.com.cn/content/dam/zte-site/res-www-zte-com-cn/mediaries/zte/investor/en\\_investor/d507ee66d4e20212ee826467bca3b55b.pdf](https://www.zte.com.cn/content/dam/zte-site/res-www-zte-com-cn/mediaries/zte/investor/en_investor/d507ee66d4e20212ee826467bca3b55b.pdf)
- <sup>xlii</sup> <https://www.congress.gov/115/bills/hr5515/BILLS-115hr5515enr.pdf>
- <sup>xliii</sup> Ibis. at page H. R. 5515—283
- <sup>xliv</sup> Ibis.
- <sup>xlv</sup> <https://2017-2021.commerce.gov/news/press-releases/2018/07/commerce-department-lifts-ban-after-zte-deposits-final-tranche-14.html>
- <sup>xlvi</sup> [https://www.zte.com.cn/content/dam/zte-site/res-www-zte-com-cn/mediaries/zte/investor/en\\_investor/d507ee66d4e20212ee826467bca3b55b.pdf](https://www.zte.com.cn/content/dam/zte-site/res-www-zte-com-cn/mediaries/zte/investor/en_investor/d507ee66d4e20212ee826467bca3b55b.pdf)
- <sup>xlvii</sup> <https://perma.cc/B7JS-E4PY>
- <sup>xlviii</sup> <https://www.loc.gov/item/global-legal-monitor/2020-10-08/china-government-releases-provisions-on-unreliable-entity-list-regime/>
- <sup>xliv</sup> [https://www.zte.com.cn/content/dam/zte-site/res-www-zte-com-cn/mediaries/zte/investor/en\\_investor/d507ee66d4e20212ee826467bca3b55b.pdf](https://www.zte.com.cn/content/dam/zte-site/res-www-zte-com-cn/mediaries/zte/investor/en_investor/d507ee66d4e20212ee826467bca3b55b.pdf)
- <sup>i</sup> Ibis.
- <sup>li</sup> <https://www.zte.com.cn/global/about/news/20210316e1.html>
- <sup>lii</sup> <https://knowledge.wharton.upenn.edu/podcast/knowledge-at-wharton-podcast/why-the-u-s-ban-on-zte-could-disrupt-telecom-supply-chains/>
- <sup>liii</sup> <https://supplychaindigital.com/company-reports/how-zte-transforming-its-supply-chain>
- <sup>liv</sup> <https://2017-2021.commerce.gov/news/press-releases/2018/07/commerce-department-lifts-ban-after-zte-deposits-final-tranche-14.html>
- <sup>lv</sup> <https://companiesmarketcap.com/wuxi-biologics/marketcap/>
- <sup>lvi</sup> <https://www.globaldata.com/company-profile/wuxi-biologics-co-ltd/>
- <sup>lvii</sup> <https://companiesmarketcap.com/wuxi-apptec/marketcap/>
- <sup>lviii</sup> Ibis
- <sup>lix</sup> <https://www.reuters.com/markets/companies/300676.SZ/>
- <sup>lx</sup> <https://www.bloomberg.com/quote/300676:CH?embedded-checkout=true>
- <sup>lxi</sup> <https://pharmaboardroom.com/articles/new-us-biosecure-act-to-target-chinese-biotechs-wuxi-and-bgi/><sup>lxii</sup> <https://www.nasdaq.com/market-activity/ipos/financial-filings?dealId=707114-64827>
- <sup>lxiii</sup> <https://pharmaboardroom.com/articles/new-us-biosecure-act-to-target-chinese-biotechs-wuxi-and-bgi/><sup>lxiv</sup> <https://www.nasdaq.com/market-activity/ipos/overview>
- <sup>^</sup>This document leveraged certain aspects of AI technology for editing or proofreading and formatting purposes. Citations and attributions have been provided truthfully and in good faith.
- <sup>^^</sup><https://selectcommitteeontheccp.house.gov/members>.
- <sup>‡</sup> <https://www.reuters.com/article/idUSKBN1IA1WF/>
- <sup>‡</sup> <https://thehill.com/policy/technology/386936-zte-ceases-business-operations-after-being-cut-off-from-us-suppliers/>

---

## Bibliography:

1. United States Senate. S. 3558, "Prohibition On Contracting With Certain Biotechnology Providers", 118th Cong., 1st sess. Introduced in Senate December 20, 2023. PDF file. <https://www.congress.gov/118/bills/s3558/BILLS-118s3558is.pdf>.
2. United States House of Representatives. H.R. 7085, BIOSECURE Act, 118th Cong., 2d sess. Introduced in House January 25, 2024. PDF file. <https://www.congress.gov/118/bills/hr7085/BILLS-118hr7085ih.pdf>.
3. "5 U.S. Code § 105 - Executive Agency," Legal Information Institute, last modified 2023. <https://www.law.cornell.edu/uscode/text/5/105>.
4. "Press Releases: Bipartisan Group of Select Committee Members Lead Coalition Introducing House and [...]." Select Committee on the Chinese Communist Party. Last modified 2023. Accessed April 6, 2024. <https://selectcommitteeontheccp.house.gov/media/press-releases/bipartisan-group-select-committee-members-lead-coalition-introducing-house-and>.
5. "ZTE Corporation," MarketScreener, accessed April 1, 2024. <https://www.marketscreener.com/quote/stock/ZTE-CORPORATION-6170649/company/>.
6. Wiley Rein LLP, "Long-Awaited Controversial NDAA Section 889 Rule on Huawei, ZTE, and Video Surveillance Companies Emerges from FAR Council," last modified 2023. <https://www.wiley.law/alert-Long-Awaited-Controversial-NDAA-Section-889-Rule-on-Huawei-ZTE-and-Video-Companies-Emerges-from-FAR-Council>.
7. "Global Biotechnology Market - Industry Trends, Growth, Analysis, Forecast," MarketDataForecast, accessed April 1, 2024. <https://www.marketdataforecast.com/market-reports/global-biotechnology-market>.
8. Polaris Market Research, "Biotechnology Market Share, Size, Trends, Industry Analysis Report, By Technology; By Application; By Region; Segment Forecast, 2023 - 2030," accessed April 2, 2024. <https://www.polarismarketresearch.com/industry-analysis/biotechnology-market>.
9. Mark Payne, Bills Aim to Halt Cash to Chinese Cos. Over Genetic Data, Law360 (Jan. 26, 2024), <https://www.law360.com/articles/1790797/bills-aim-to-halt-cash-to-chinese-cos-over-genetic-data>.
10. Ropes & Gray LLP, "The Biosecure Act: A Review of the Bill, Responses, and Possible Repercussions," last modified March 2024. <https://www.ropesgray.com/en/insights/alerts/2024/03/the-biosecure-act-a-review-of-the-bill-responses-and-possible-repercussions>.
11. Interoffice Memo, Committee on Homeland Security and Governmental Affairs (March 6, 2024) <https://www.hsgac.senate.gov/wp-content/uploads/Committee-Record-2024-03-06.pdf>.
12. "Executive Order on Preventing Access to Americans' Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern," The White House, February 28, 2024. <https://www.whitehouse.gov/briefing-room/presidential-actions/2024/02/28/executive-order-on-preventing-access-to-americans-bulk-sensitive-personal-data-and-united-states-government-related-data-by-countries-of-concern/>.
13. "National Security Division Provisions Regarding Access to Americans' Bulk Sensitive Personal Data and United States Government-Related Data," Federal Register, March 5, 2024. <https://www.federalregister.gov/documents/2024/03/05/2024-04594/national-security-division-provisions-regarding-access-to-americans-bulk-sensitive-personal-data-and>.

- 
13. "How Our Laws Are Made," Congress.gov, accessed March 25, 2024. <https://www.congress.gov/help/learn-about-the-legislative-process/how-our-laws-are-made#HowOurLawsAreMade-LearnAbouttheLegislativeProcess-ConsiderationbyCommittee>.
  14. "Committees," U.S. Senate, accessed March 22, 2024. [https://www.senate.gov/committees/hearings\\_meetings.htm](https://www.senate.gov/committees/hearings_meetings.htm).
  15. "Unreliable Entity List," Perma.cc, captured April 2, 2024. <https://perma.cc/B7JS-E4PY>.
  16. Reed Smith LLP, "China Sanctions U.S. Companies for First Time Under Unreliable Entity List," last modified March 2023. <https://www.reedsmith.com/en/perspectives/2023/03/china-sanctions-us-companies-for-first-time-under-unreliable-entity-list>.
  17. ZTE, "Annual Report 2023," ZTE Corporation, 2023. PDF. [https://www.zte.com.cn/content/dam/zte-site/res-www-zte-com-cn/mediares/zte/investor/en\\_investor/d507.pdf](https://www.zte.com.cn/content/dam/zte-site/res-www-zte-com-cn/mediares/zte/investor/en_investor/d507.pdf).
  18. "H.R.5515 - John S. McCain National Defense Authorization Act for Fiscal Year 2019," 115th Cong. (2018). PDF. <https://www.congress.gov/115/bills/hr5515/BILLS-115hr5515enr.pdf>.
  19. "Section 889 of the National Defense Authorization Act," Acquisition.gov, accessed April 3, 2024. PDF. [https://www.acquisition.gov/sites/default/files/page\\_file\\_uploads/889-Flyer-Approved.pdf](https://www.acquisition.gov/sites/default/files/page_file_uploads/889-Flyer-Approved.pdf).
  20. U.S. Department of Commerce. "Commerce Department Lifts Ban After ZTE Deposits Final Tranche of \$1.4 Billion Penalty." Press Release. Last modified July 2018. <https://2017-2021.commerce.gov/news/press-releases/2018/07/commerce-department-lifts-ban-after-zte-deposits-final-tranche-14.html>.
  21. National Institutes of Health. "NIH to Launch Public-Private Partnership to Speed COVID-19 Vaccine and Treatment Options." News Release. Last modified 2020. <https://www.nih.gov/news-events/news-releases/nih-launch-public-private-partnership-speed-covid-19-vaccine-treatment-options>.
  22. Knowledge@Wharton. "Why the U.S. Ban on ZTE Could Disrupt Telecom Supply Chains." Podcast. Wharton School of the University of Pennsylvania. Last modified 2018. <https://knowledge.wharton.upenn.edu/podcast/knowledge-at-wharton-podcast/why-the-u-s-ban-on-zte-could-disrupt-telecom-supply-chains/>.
  23. Supply Chain Digital. "How ZTE Is Transforming Its Supply Chain." Company Report. Last modified 2020. <https://supplychaindigital.com/company-reports/how-zte-transforming-its-supply-chain>.
  24. PharmaBoardroom. "New US Biosecure Act to Target Chinese Biotechs WuXi and BGI." Article. Last modified 2020. <https://pharmaboardroom.com/articles/new-us-biosecure-act-to-target-chinese-biotechs-wuxi-and-bgi/>.
  25. Yahoo Finance. "2269.HK - WuXi Biologics (Cayman) Inc. Stock Price History." Yahoo. Accessed April 2, 2024. <https://finance.yahoo.com/quote/2269.HK/history/>.
  26. "The Wall Street Journal." "WuXi Companies' Shares Slide Amid Concerns Over Proposed U.S. Bill." Accessed April 2, 2024. <https://www.wsj.com/business/wuxi-companies-shares-slide-amid-concerns-over-proposed-u-s-bill-bb2827c5>.

- 
27. "Actions - S.3558 - 118th Congress (2023-2024): Prohibition On Contracting With Certain Biotechnology Providers," Congress.gov, last modified 2023. <https://www.congress.gov/bill/118th-congress/senate-bill/3558/all-actions>.
  28. Complete Genomics. "Open Letter to the Genomics Community." Accessed April 6, 2024. <https://www.completegenomics.com/open-letter-to-genomics-community/>.
  29. WuXi Biologics. "CLARIFICATION ANNOUNCEMENT." PDF. Accessed April 6, 2024. <https://doc.irasia.com/listco/hk/wuxibiologics/announcement/a240129.pdf>
  30. Sijia Jiang and James Pomfret; Additional reporting by Sheila Dang in New York; Editing by Jason Neely and Marguerita Choy. "China's ZTE says main business operations cease due to U.S. ban." Reuters, 2018. <https://www.reuters.com/article/idUSKBN1IA1WF/>. Accessed April 2, 2024.
  31. Harper Neidig. "ZTE ceases business operations after being cut off from US suppliers." The Hill, 2018. <https://thehill.com/policy/technology/386936-zte-ceases-business-operations-after-being-cut-off-from-us-suppliers/>. Accessed April 2, 2024.
  32. CompaniesMarketCap.com. "WuXi Biologics Market Cap." Accessed April 6, 2024. <https://companiesmarketcap.com/wuxi-biologics/marketcap/>.
  33. GlobalData. "WuXi Biologics Co., Ltd. - Company Profile." Accessed April 6, 2024. <https://www.globaldata.com/company-profile/wuxi-biologics-co-ltd/>.
  34. CompaniesMarketCap.com. "WuXi AppTec Market Cap." Accessed April 6, 2024. <https://companiesmarketcap.com/wuxi-apptec/marketcap/>.
  35. Reuters. "Company Profile - 300676.SZ." Accessed April 6, 2024. <https://www.reuters.com/markets/companies/300676.SZ/>.
  36. Bloomberg. "Stock Quote - 300676:CH." Accessed April 6, 2024. <https://www.bloomberg.com/quote/300676:CH?embedded-checkout=true>.
  37. PharmaBoardroom. "New US Biosecure Act to Target Chinese Biotechs WuXi and BGI." Accessed April 6, 2024. <https://pharmaboardroom.com/articles/new-us-biosecure-act-to-target-chinese-biotechs-wuxi-and-bgi/>.
  38. Nasdaq. "IPOs Financial Filings." Accessed April 6, 2024. <https://www.nasdaq.com/market-activity/ipo/financial-filings?dealId=707114-64827>.